January 8, 2024 04:49 AM ESTUpdated 08:42 AM

Novartis strikes $250M buyout for Merck Serono spinout's autoimmune 'pipeline-in-a-drug'

Amber Tong

Senior Editor

Novartis is set to acquire autoimmune-focused Calypso Biotech for $250 million upfront, laying claim to the first pharma buyout of 2024 just hours before the JP Morgan Healthcare Conference kicks off.

Amsterdam-based Calypso is all about the inflammatory cytokine interleukin-15, or IL-15. CALY-002, its anti-IL-15 antibody, is a “pipeline-in-a-drug with potential in dermatology, gastro-intestinal and rheumatology indications,” according to the company’s statement.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Novartis strikes $250M buyout for Merck Serono spinout's autoimmune 'pipeline-in-a-drug'

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

Teva to close additional manufacturing sites as it enters next phase of 'pivot to growth'

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

AstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future commercial demand'

Medical Affairs: The Critical Link Between Science, Physicians and Patients

No­var­tis strikes $250M buy­out for Mer­ck Serono spin­out's au­toim­mune 'pipeline-in-a-drug'

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

Te­va to close ad­di­tion­al man­u­fac­tur­ing sites as it en­ters next phase of 'piv­ot to growth'

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

As­traZeneca pulls Covid-19 vac­cine glob­al­ly as the phar­ma sees 'no fu­ture com­mer­cial de­mand'

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Novartis strikes $250M buyout for Merck Serono spinout's autoimmune 'pipeline-in-a-drug'

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

Teva to close additional manufacturing sites as it enters next phase of 'pivot to growth'

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

AstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future commercial demand'

Medical Affairs: The Critical Link Between Science, Physicians and Patients